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Background: 22q11.2 deletion syndrome (22q11.2DS) is a common microdeletion syndrome, which occurs in
approximately 1:4000 births. Familial autosomal dominant recurrence of the syndrome is detected in about 8-28%
of the cases. Aim of this study is to evaluate the intergenerational and intrafamilial phenotypic variability in a cohort
of familial cases carrying a 22q11.2 deletion.
Methods: Thirty-two 22q11.2DS subjects among 26 families were enrolled.
Results: Second generation subjects showed a significantly higher number of features than their transmitting parents
(212 vs 129, P = 0.0015). Congenital heart defect, calcium-phosphorus metabolism abnormalities, developmental and
speech delay were more represented in the second generation (P < 0.05). Ocular disorders were more frequent in the
parent group. No significant difference was observed for the other clinical variables. Intrafamilial phenotypic heterogeneity
was identified in the pedigrees. In 23/32 families, a higher number of features were found in individuals from the second
generation and a more severe phenotype was observed in almost all of them, indicating the worsening of the phenotype
over generations. Both genetic and epigenetic mechanisms may be involved in the phenotypic variability.
Conclusions: Second generation subjects showed a more complex phenotype in comparison to those from the first
generation. Both ascertainment bias related to patient selection or to the low rate of reproductive fitness of adults with a
more severe phenotype, and several not well defined molecular mechanism, could explain intergenerational and
intrafamilial phenotypic variability in this syndrome.
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Chromosome 22q11.2 deletion syndrome (22q11.2DS),
also known as DiGeorge or velocardiofacial syndrome
(OMIM#188400), occurs in approximately 1:4000 live
births [1,2]. Major clinical features include facial anoma-
lies, conotruncal cardiac defects, palatal anomalies, neo-
natal hypocalcaemia, mild to moderate immune deficiency
related to thymic a/hypoplasia [3-5], developmental and
speech delay [6]. Ocular, renal and skeletal anomalies may* Correspondence: pignata@unina.it
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reproduction in any medium, provided the oralso be found. However, the syndrome has a very wide
spectrum of phenotypic features [7,8]. Evidence high-
lighted that subjects carrying the deletion may have only
mild phenotypes [9,10]. Psychiatric or autoimmune disor-
ders [11] can be the features leading to the diagnosis in
adolescents and adults, and, in particular, among adults,
they may be the unique clinical feature [12,13]. The identi-
fication of subjects with attenuated phenotypes is leading
to the understanding that the syndrome is more frequent
than previously thought and to focus on novel atypical
presentations. A wide clinical variability has also been
reported even within the same family [9,10,14,15] and a
phenotypic discordance has been described among mono-
zygotic twins [16,17]. Genetic modifiers, chance asso-
ciation or environmental interactions have been proposedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or post zygotic second hit have also been hypothesized as
potential mechanisms underlying such phenotypic dis-
cordance, even though, to date, no definitive explanation
is available.
The deletion results from non allelic homologous re-
combination, occurring during meiosis and mediated by
low-copy repeats (LCR) on chromosome 22 [18-20].
Most patients have a deletion of the same 3 Mb region
on 22q11.2, including about 30 genes, whereas in 8% of
the cases a smaller deletion of 1.5 Mb, which contains
24 genes, is found. So far, no correlation between the
severity of the phenotype and the different size of the
deletion has been documented [21]. Both deletions in-
clude the TBX1 gene, a member of the T-box family
genes. Mice, haploinsufficient for TBX1, share several
features with humans carrying the homologous deletion,
and, in particular, structural cardiac anomalies [22]. In-
terestingly, both gain or loss of function mutations in
TBX1 have been reported in human subjects exhibiting
a DiGeorge-like phenotype [23].
In most cases, the deletion is a sporadic event, while
in 8-28% of the cases the syndrome is inherited in an
autosomal dominant fashion [8,10,24-26].
Several studies have analyzed the phenotypic varia-
bility of the syndrome, but an extensive and conclusive
intergenerational and intrafamilial comparison has not
yet been reported.
The aim of this study is to perform an interge-
nerational and intrafamilial comparison of the clinical
phenotype in a cohort of patients affected with inherited
chromosome 22q11.2DS.
Methods
Patients
Thirty-two subjects (18 females) affected with familial
22q11.2DS from 26 families, were enrolled into the study.
The study and data collection, approved by the local Ethics
Committee for Biomedical activities “Carlo Romano”,
have been performed upon informed consent and in com-
pliance with the Helsinki Declaration (http://www.wma.
net/en/30publications/10policies/b3/index.html). Within
the group, 17 subjects were from the Italian Network for
Primary Immunodeficiencies (IPINET) Registry, followed
at 8 Italian Centers, and 15 were referred to two Genetic
Units. In 4 families, 2 affected siblings were diagnosed and
in one further family, 3 subjects were identified. Mean
age +/− SD was 10.4 +/− 7.23 years (range 4 months-
31 years). The parent carrying the deletion was the
mother in 17 cases (65%) and the father in 9 (35%).
Mean age +/− SD of carrier parents was 39.8 +/− 7.9 years
(range 21–58 years). We found a preferential maternal
transmission, in keeping with the recent observation that
female sex represents a significant positive predictor offitness. All the parents were identified as affected by
22q11.2DS after the birth of a child with the deletion. All
patients, but two, were Caucasian. Demographical features
are reported in Additional file 1: Table S1. Clinical data of
the second generation subjects were obtained, upon in-
formed consent, through the IPINET Registry or from the
referring Units. Data on parents carrying the deletion were
collected at each Center. Each subject underwent a clinical
and laboratory evaluation protocol (IPINET protocol for
22q11.2DS) available at the site http://www.aieop.org. The
protocol included cardiologist examination, echocardiog-
raphy and abdominal ultrasound, which were performed
in order to exclude subclinical cardiac or abdominal de-
fects in asymptomatic subjects. To exclude thyroid and
calcium-phosphorus abnormalities, the serum levels of
calcium, phosphorus, parathyroid hormone, TSH and FT4
were evaluated. History of speech therapy or speech pa-
thologist interventions were recorded for the evaluation of
language disorders. The Wechsler Intelligence Scale for
Children (WISC) and the Wechsler Adult Intelligence
Scale (WAIS) were used for the assessment of cognitive
function in subjects of the second generation and in their
parents, respectively. Each Center reported the presence/
absence of intellectual disability which was defined as an
IQ under 70. Neuropsychiatric evaluation was performed
by skilled clinicians using the Schedule For Affective
Disorders and Schizophrenia for School-aged Children,
Present and Lifetime (K-SADS-PL). The second gene-
ration subjects, older than 18 years, and their parents were
interviewed with the Structured Clinical Interview for
Axis I DSM IV Disorders (SCID).
Among the clinical features, birth defects, facial anom-
alies, gastrointestinal disorders, infections and auto-
immune manifestations were recorded. History of
neonatal hypocalcaemia was also considered. In 6 fam-
ilies, data were also obtained from the non-deleted par-
ent, to exclude potential interfering factors not related
to the 22q11.2 deletion.
Intrafamilial phenotypic variability was assessed through
the evaluation of the clinical phenotype in each parent–
child couple. Since in 5 families more than 1 subject with
the inherited deletion was detected, the phenotype was
analyzed in a total number of 32 parent–child pairs from
the 26 families.
Cytogenetic analysis
The diagnosis of 22q11.2DS was performed by fluore-
scence in situ hybridization (FISH) analysis and/or multi-
plex ligation-dependent probe amplification (MLPA) using
probes for 22q11 region in all affected patients. In one
case, the diagnosis was obtained through a CGH array
with whole-genome oligonucleotide microarray Agilent
Technologies (Santa Clara, CA) according to the manufac-
turer protocol.
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Statistical analysis was performed using the Student”s
t test or the Fisher exact Test. Values of P < 0.05 were
considered statistically significant. The calculations
were performed using InStat software.
Results
Intergenerational clinical phenotypic comparison
Seventeen clinical variables were evaluated in subjects of
the second generation and their parents (Table 1), for a
total number of 544 and 442 variables in the first and
second group, respectively. Overall, affected subjects of
the second generation showed a significantly higher num-
ber of features than their parents (212 vs 129, P = 0.0015).
In particular, congenital heart defect (CHD) (62.5 vs
7%, P < 0.0001), developmental delay (71.8 vs 42.3%,
P = 0.032), speech delay (75 vs 46.1%, P = 0.031)
and calcium-phosphorus abnormalities (37.5 vs 3.8%,
P = 0.0033) were more represented in the second gene-
ration. Conversely, ocular disorders were more frequent
in the parents than in their affected children (3.1 vs 23%,
P = 0.037). Psychiatric (12.5 vs 34.6%), autoimmune (12.5
vs 19.2%) and dental disorders (25 vs 38.4%) tended to be
more frequent in the older generation, even though the
differences did not reach a statistical significance. NoTable 1 Clinical characteristics of second generation
subjects and parents carrying the 22q11.2 deletion
Second generation Parents
Total number of subjects 32 26
N (%) N (%) p
Facial anomalies 29 (90.6) 24 (92.3) 1
Congenital heart defect 20 (62.5) 2 (7) <0.0001
Ca-P abnormalities 12 (37.5) 1 (3.8) 0.0033
Palatal anomalies 18 (56.2) 13 (50) 0.79
ENT anomalies 4 (12.5) 2 (7) 0.68
Renal disorders 7 (21.8) 2 (7) 0.16
Ocular disorders 1 (3.1) 6 (23) 0.037
Neurological disorders 3 (9.3) 1 (3.8) 0.62
Dental anomalies 8 (25) 10 (38.4) 0.39
Skeletal anomalies 15 (46.8) 10 (38.4) 0.6
Gastrointestinal disorders 8 (25) 2 (7) 0.16
Psychiatric disorders 4 (12.5) 9 (34.6) 0.06
Language delay 24 (75) 12 (46.1) 0.031
Developmental delay 23 (71.8) 11 (42.3) 0.032
Learning difficulty 23 (71.8) 16 (61.5) 0.57
Autoimmunity 4 (12.5) 5 (19.2) 0.71
Infections 9 (28.1) 3 (11.5) 0.19
Only severe infections (sepsis, pneumoniae), requiring hospitalization, or
history of recurrent infections were considered. Bold indicate P values
considered statistically significant.statistically significant difference was observed for the
other phenotypic features. About 15% of the clinical fea-
tures were diagnosed during the study.
We next compared the anatomic type of CHD bet-
ween the 2 groups. We found that in the 20% of the
subjects of the second generation with CHD, each indi-
vidual patient had more than 1 abnormality, whereas in
the parent group none of them had a more severe defect.
A cyanotic CHD was found only in the 35% of the group
with the cardiac defect. In particular, among these pa-
tients, we found that 7/20 subjects of the second gene-
ration exhibited a tetralogy of Fallot (TOF) and only 1/20
truncus arteriosus (TA). Among those with non cyanotic
CHD, a patent ductus arteriosus (PDA) was observed in
4/20, atrial septal defects (ASD) in 4/20, interrupted aortic
arch (IAA) in 4/20, ventricular septal defects (VSD) in
3/20, pulmonary valve stenosis (PVS) in 1/20 and other in
2/20. In the parent group, the anomalies found were a
PDA in one case and a double aortic arch (DAA) in the
other one.
With regard to calcium-phosphorus metabolism abnor-
malities, 9 subjects in the second generation presented
with neonatal hypocalcemia, and in 2 of them a hypopara-
thyroidism was later diagnosed. Overall, at any age, a total
of 5/32 (15.6%) of them received a full diagnosis of hypo-
parathyroidism. Only 1 subject of the parent group was
affected with asymptomatic hypoparathyroidism.
Although the prevalence of the palatal defects was simi-
lar in the 2 groups (56 and 50%, respectively), we next
compared the type of the defect and made a comparison.
Within the group of patients of the second generation, 1
subject had cleft palate and bifid uvula, 16 velopharyngeal
insufficiency, 4 hypernasal speech and 4 high arched
palate. In the parent group, 11 had velopharyngeal insuf-
ficiency, 3 hypernasal speech, 1 high arched palate. Only
in two parents, a cleft palate was observed. Thus, no re-
markable difference was found for these variables.
Psychiatric disorders were more frequent in the parent
group, even though the difference did not reach statistical
significance (P = 0.06). We found that in the parent group,
anxiety was observed in 5/26, mood disorders in 3/26,
attention-deficit/hyperactivity disorders in 3/26, beha-
vioral anomalies in 3/26, schizophrenia in 2/26, psychotic
disorders not otherwise specified (NOS) in 2/26 and
phobia in 1/26. Within the second generation group, 2 of
them had behavioral abnormalities represented by trend
to social isolation and rejection, impairment in social and
daily living skills and low self-esteem, 1 also showed adap-
tive abnormalities, and the other one an attention deficit
disorder. Schizophrenia was observed in 1 subject of the
second generation, who, however, was 31 years-old.
Ocular defects were the only anomaly frequently ob-
served in the parental generation, consisting in refractive
defects (3/6), strabismus (2/6), retinal vessel abnormalities
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child with ocular defect had retinal vessels abnormalities.
Intrafamilial clinical phenotypic comparison
With regard to the intrafamilial phenotypic variability, in
23 out of the 32 child/parent couples a higher number
of features was found in the second generation, although
in 6 couples the number of features was higher in the
parents’ generation and in the remaining 3 couples no
difference was found (Figure 1). None of the couples
with higher number of features in the parents’ gene-
ration had a CHD or hypoparathyroidism.
We then performed an intrafamilial evaluation of the
clinical severity of the phenotype with regard to the
prominent clinical features, whose prevalence was statis-
tically different between the 2 groups, namely CHD,
anomalies of the calcium-phosphorus metabolism, deve-
lopmental and/or speech delay (Table 2).
In particular, we observed that CHD was present in 18
couples only in the second generation and, in one case,
only in the first generation. In the couple in which both
members were affected, the parent exhibited a PDA,
whereas his child was affected with IAA, thus confir-
ming the lack of phenotypic correspondence. Calcium-
phosphorus abnormalities were found in 11 subjects of
the second generation, and the only parent with asymp-
tomatic hypoparathyroidism had a child who presented
with hypocalcaemia. In 15 couples speech delay was ex-
clusively observed in the second generation whereas in 5
couples only in the first generation. In the remaining 9
couples both members were affected. In 16 couples, de-
velopmental delay was exclusively found in the second0
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Figure 1 Intrafamilial phenotypic comparison. A higher number of feat
couples the number of features was higher in the parents’ generation and
indicate the families with 2 or more second generation affected subjects. *generation, in 4 cases only in the first generation and in
8 couples both subjects were affected.
To rule out the interference of factors not related to
the 22q11.2 deletion, in 6 families, data were collected
also from the non-deleted parent. Of note, none of them
had a CHD, while 2 children in this subgroup were
affected. One subject reported learning and behavioral
problems, but not intellectual disabilities, while in an-
other case a borderline IQ of 68 was determined.
Furthermore, in the families with more than one af-
fected child, a milder phenotype was observed in parents
than in children, even though the 5 subjects of the second
generation, who were diagnosed first, had a higher num-
ber of the major clinical features compared to their 6 sib-
lings (16 core features vs 11).
Discussion and conclusions
We have compared the clinical phenotype of a cohort of
32 subjects affected with inherited 22q11.2DS and their
transmitting parents.
In this study, we found a higher number of clinical
features and a more severe phenotype in the second
generation, which exhibited a higher number of more
severe conditions. CHD, abnormalities of the calcium-
phosphorus metabolism, developmental and/or speech
delay were more represented in children than in parents.
It should be considered that, in the past decades, severe
CHD was associated with a high neonatal and infant mor-
tality. This evidence was thought to have an appreciable
impact on reducing the reproductive fitness of 22q11.2DS
patients with CHD. More recently, however, with the
improvement of cardiac surgery strategies, it is suggested6 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
uple
**
ures were observed in the second generation in 23 couples. In 6
in the remaining 3 couples no difference was found. The brackets
indicates the proband within these families.
Table 2 Intrafamilial comparison of the clinical severity of the phenotype
Couple Congenital heart defect Ca-P abnormalities Speech delay Developmental delay
Affected subject Parent Affected subject Parent Affected subject Parent Affected subject Parent
1 yes no yes yes no yes yes no
2 yes no yes no yes no no no
3 yes no no no no yes yes no
°4 no no yes no no yes yes no
°5δ yes no yes no yes yes yes no
6 yes no no no yes yes yes yes
7 yes no yes no yes no yes no
8 no no no no yes no yes no
9 no no no no yes no yes no
10 no yes yes yes yes yes no no
°11 yes no yes no no no yes no
°12δ yes no no no yes no yes no
13 no no no no yes no no yes
°14 no no no no yes no yes yes
°15δ yes no no no yes no no yes
16 no no no no yes no yes no
17 yes no no no yes yes yes yes
18 yes no no no yes yes yes yes
19 yes no no no yes yes no yes
20 yes yes no yes yes yes yes no
21 yes no yes no yes yes yes yes
22 yes no yes no yes yes yes yes
23 yes no yes no yes no yes yes
°24 no no no no yes no yes no
°25 no no no no yes no yes no
°26δ yes no yes no yes no yes no
27 yes no yes no no yes no yes
28 no no no no yes yes yes yes
29 no no no no yes no yes no
°30δ yes no no no yes no yes no
°31 no no no no no no no no
32 yes no no no no no no no
°Couple of siblings; δFirst individual to seek medical attention for genetic evaluation.
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transmission of 22q11.2 deletion is primarily due to the
severity of the neuropsychiatric phenotype and intellectual
disabilities [27].
The only anomalies more frequent in the parental
generation were ocular abnomalities. Since most of
them, in particular refractive defects and cataract
usually develop during older age, we could not exclude
a bias related to the different ages of the subjects in the
two groups.When an intrafamilial comparison of the phenotypic
complexity was performed, a higher prevalence of clinical
features were found in the second generation. When the
comparison concerned the prominent clinical features,
whose prevalence was statistically different between the 2
groups, namely CHD, calcium-phosphorus metabolism
anomalies, developmental delay and speech delay, we
observed that in almost all parent/child couples these
major features were more frequent in the second gene-
ration. In previous studies [9,10,13-15,24], an intrafamilial
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comparison of intergenerational clinical features has not
been performed. An ascertainment bias could partially ex-
plain this finding, since the first subject diagnosed within
a family is likely to be more severely affected. Moreover,
our observation may also be explained by a bias related to
the low rate of reproductive fitness of adults with a more
severe phenotype.
As to developmental delay, the presence of environmen-
tal intellectual disabilities may obviously per se influence
the mental development of the offspring, because of psy-
chosocial deprivation. However, it should be emphasized
that in our cohort the majority of the subjects with
developmental delay have a parent without intellectual
disability. Moreover, in the 6 families in which also the
non-deleted parent was studied, the lack of a clear corre-
lation between environment and the child’ development
was noted. As expected, psychiatric disorders were more
represented in the first generation, however, the difference
was not significant thus suggesting the need of an accurate
psychiatric management since childhood.
Several genes, such as TBX1 [28], HIRA, UFD1L [29]
and CRKL [30], within the 22q11 region have been consid-
ered to be implicated in the pathogenesis of the syndrome.
The 22q11.2 phenotype is a developmental field defect,
and a DiGeorge-like phenotype may also occur in the ab-
sence of the deletion [31], as in diabetic [32] and retinoic
acid embryopathy, fetal alcohol syndrome, CHARGE [33]
and Fraser syndromes, as well as other chromosomal
anomalies, such as 10p13, 17p13, 4q34.1q35.2 [34-36],
indicating that several molecules in a common genetic
pathway or in functionally related pathways may be
involved in 22q11.2DS clinical manifestations.
Several hypotheses have so far been proposed to explain
intergenerational and intrafamilial phenotypic variability
in genetic syndromes. Deletions of different sizes and
location and the extension of an unstable mutation at the
22q11.2 locus could explain the clinical variability [37].
Evidence indicates that TBX1 gene is sensitive to
altered dosage [38], thus leading to the hypothesis that
additional alterations of the other allele may explain the
clinical variability. In humans, this does not seem to be
the case, in that so far DNA variations in TBX1 locus on
the remaining allele were not found in 22q11.2DS pa-
tients exhibiting a variable cardiovascular expression and
palatal defects. Thus, it is likely that gene modifiers not
related to chromosome 22 may be implicated [39,40].
The increased risk of cardiac defects observed in un-
affected relatives of 22q11.2DS subjects with CHD, sug-
gested a potential role for genes outside the DiGeorge
critical region [41,42]. However, studies aimed at identi-
fying genetic factors outside of the 22q11,2 region, such as
VEGFA [43] or folate-related genes [44] failed to reveal
any association. It should be noted that in the subgroup offamilies in whom also the non-deleted parent was studied,
no CHD was noted suggesting the absence of interfering
genetic factors not related to the 22q11.2 deletion in this
context.
A copy-number variation may explain a reduced pene-
trance of some disease-causing mutations [45]. A genetic
compensatory effect has also been documented in families
of 22q11.2DS subjects, whose clinically normal parent
carried 22q11.2 deletion compensated by an insertion of
the 22q11.2 critical region inside the other copy of the
chromosome [46]. Finally, a mosaic status in the carrier
parent, even though rare, could be the explanation of the
variable and more benign phenotype. At the moment, we
cannot yet exclude the presence of a concomitant duplica-
tion or copy number variations in the former generation,
since further studies with interphase FISH or array-CGH
are required to rule out this hypothesis.
During development, gene expression is accurately or-
chestrated in time and space in a program that involves
enzymes controlling nucleosome remodeling, histone mo-
dification and DNA methylation [47]. A demonstration
that an epigenetic alteration could result in a DiGeorge
syndrome phenocopy has been recently documented in
mutant mice lacking the MOZ histone acetyltransferase
[48]. Thus, failure of these fine tuned mechanisms could
result in an interference of the phenotypic expression.
In our study we also observed that some clinical fea-
tures were more represented in the previous generation,
although the difference did not reach the statistical sig-
nificance for the limited number of subjects studied. In
keeping with recent findings, we observed a higher inci-
dence of psychiatric disorders in the older generation.
The identification of adults with a milder phenotype de-
serves careful attention since a later onset illness associ-
ated with 22q11.2DS has been reported, highlighting the
possibility that along with psychiatric disorders, also treat-
able conditions such as symptomatic or asymptomatic
hypocalcaemia, thrombocytopenia and hypothyroidism
may occur [49]. Early recognition of these features [50]
could provide the benefit of an early treatment [51-53].
Advantages and limitations of the study
This is the largest cohort of subjects affected with familial
22q11.2DS. A detailed characterization of the clinical fea-
tures of such subjects, and an intergenerational/intrafa-
milial clinical comparison has been performed. The
observation that within the families, the patients who were
first diagnosed had a higher number of core features as
compared to their siblings or parents would suggest an as-
certainment bias, even though the clinical phenotype of
the parents was milder compared to their children. An-
other possible explanation could be the co-inheritance of
a further genetic defect from the non-affected parent. This
seems unlikely since this co-inheritance should have
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phenotype. As for the CHD, it should be noted that none
of the non-affected parents had a CHD, thus excluding, at
least for this feature, this hypothesis.
Additional file
Additional file 1: Table S1. Demographic characteristics of the
22q11.2DS subjects.
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